Minerva
Minerva
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6651 (Published 19 October 2011) Cite this as: BMJ 2011;343:d6651
- Thomas M Jenkins, specialty registrar in neurology,
- M Reuber, reader in neurology and consultant neurologist
- 1Sheffield Institute of Translational Neuroscience, Sheffield S10 2HQ, UK; Royal Hallamshire Hospital, Sheffield S10 2JF
Although it is well known that rifampicin, an anti-tuberculous drug, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.